tetano
Editor, Senior Moderator
BMC Res Notes. 2018 Apr 14;11(1):244. doi: 10.1186/s13104-018-3349-y.
[h=1]Descriptive study of severe hospitalized cases of laboratory-confirmed influenza during five epidemic seasons (2010-2015).[/h] Torner N[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Mart?nez A[SUP]4,[/SUP][SUP]5[/SUP], Basile L[SUP]4[/SUP], Mosquera M[SUP]6[/SUP], Ant?n A[SUP]7[/SUP], Rius C[SUP]5,[/SUP][SUP]8[/SUP], Sala MR[SUP]4[/SUP], Minguell S[SUP]4[/SUP], Plasencia E[SUP]4[/SUP], Carol M[SUP]4[/SUP], Godoy P[SUP]4,[/SUP][SUP]5[/SUP], Follia N[SUP]4[/SUP], Barrabeig I[SUP]4[/SUP], Marcos MA[SUP]6[/SUP], Pumarola T[SUP]7[/SUP], Jan? M[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] The Plan of Information on Acute Respiratory Infections in Catalonia (PIDIRAC) included the surveillance of severe hospitalized cases of laboratory-confirmed influenza (SHCLCI) in 2009. The objective of this study was to determine the clinical, epidemiological and virological features of SHCLCI recorded in 12 sentinel hospitals during five influenza seasons.
[h=4]RESULTS:[/h] From a sample of SHCLCI recorded during the 5 influenza epidemics seasons from 2010-2011 to 2014-2015, Cases were confirmed by PCR and/or viral isolation in cell cultures from respiratory samples. A total of 1400 SHCLCI were recorded, 33% required ICU admission and 12% died. The median age of cases was 61 years (range 0-101 years); 70.5% were unvaccinated; 80.4% received antiviral treatment (in 79.6 and 24% of cases within 48 h after hospital admission and the onset of symptoms, respectively); influenza virus A [37.9% A (H1N1)pdm09, 29.3% A (H3N2)] was identified in 87.7% of cases. Surveillance of SHCLCI provides an estimate of the severity of seasonal influenza epidemics and the identification and characterization of at-risk groups in order to facilitate preventive measures such as vaccination and early antiviral treatment.
[h=4]KEYWORDS:[/h] Antiviral drugs; Epidemiology; Influenza; Surveillance; Vaccine
PMID: 29655370 DOI: 10.1186/s13104-018-3349-y
Free full text
[h=1]Descriptive study of severe hospitalized cases of laboratory-confirmed influenza during five epidemic seasons (2010-2015).[/h] Torner N[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Mart?nez A[SUP]4,[/SUP][SUP]5[/SUP], Basile L[SUP]4[/SUP], Mosquera M[SUP]6[/SUP], Ant?n A[SUP]7[/SUP], Rius C[SUP]5,[/SUP][SUP]8[/SUP], Sala MR[SUP]4[/SUP], Minguell S[SUP]4[/SUP], Plasencia E[SUP]4[/SUP], Carol M[SUP]4[/SUP], Godoy P[SUP]4,[/SUP][SUP]5[/SUP], Follia N[SUP]4[/SUP], Barrabeig I[SUP]4[/SUP], Marcos MA[SUP]6[/SUP], Pumarola T[SUP]7[/SUP], Jan? M[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] The Plan of Information on Acute Respiratory Infections in Catalonia (PIDIRAC) included the surveillance of severe hospitalized cases of laboratory-confirmed influenza (SHCLCI) in 2009. The objective of this study was to determine the clinical, epidemiological and virological features of SHCLCI recorded in 12 sentinel hospitals during five influenza seasons.
[h=4]RESULTS:[/h] From a sample of SHCLCI recorded during the 5 influenza epidemics seasons from 2010-2011 to 2014-2015, Cases were confirmed by PCR and/or viral isolation in cell cultures from respiratory samples. A total of 1400 SHCLCI were recorded, 33% required ICU admission and 12% died. The median age of cases was 61 years (range 0-101 years); 70.5% were unvaccinated; 80.4% received antiviral treatment (in 79.6 and 24% of cases within 48 h after hospital admission and the onset of symptoms, respectively); influenza virus A [37.9% A (H1N1)pdm09, 29.3% A (H3N2)] was identified in 87.7% of cases. Surveillance of SHCLCI provides an estimate of the severity of seasonal influenza epidemics and the identification and characterization of at-risk groups in order to facilitate preventive measures such as vaccination and early antiviral treatment.
[h=4]KEYWORDS:[/h] Antiviral drugs; Epidemiology; Influenza; Surveillance; Vaccine
PMID: 29655370 DOI: 10.1186/s13104-018-3349-y
Free full text